Inhibition of PLA by crizanlizumab vs inclacumab in control or SCD human blood. Flow cytometry was used to assess the inhibition of PLA by different concentrations of crizanlizumab vs inclacumab in TRAP-6–treated blood of healthy control humans (N = 10) (A) and patients with SCD (N = 10) (B). Data represent the mean (±standard error) percent inhibition of PLA at each concentration by 2 mAbs and were compared using the paired Student t test. ∗P ≤ .05; ∗∗P ≤ .01; ∗∗∗P ≤ .001; ∗∗∗∗P ≤ .0001. SEM, standard error of the mean.